R1 RCM

Capital is deployed through the operating business that manages the full revenue cycle for health systems. The model combines upfront investment in automation and AI with recurring revenue from yield improvements and cost reductions. R1 does not operate a traditional fund structure; instead, it enters multiyear operating partnerships where the firm shares in the incremental cash collected.

R37 is R1's dedicated AI lab that develops reasoning, language, voice and capture models for revenue cycle tasks. It functions as an internal R&D engine that produces the agentic software underpinning the firm's Phare platform. This makes technology development a core competency rather than a capability bought from third parties.

A 16-person leadership team, led by Joseph Flanagan, directs all investment and operating activity. Specific investment committee structures are not disclosed publicly. Day-to-day execution is spread across technology, operations and client partnership leaders who manage the embedded teams inside hospital systems.

The firm's known deployment flows entirely into its own operating model—building Phare product modules, funding the R37 AI lab, and staffing on-site operator teams. The strategic partnership with Sierra signals a willingness to co-develop AI capabilities, but there is no public evidence R1 makes third-party venture investments.

The firm reports three headline numbers: over $6 billion in annual revenue recovery processed, more than 200 million tasks automated, and partnerships with 95 of the top 100 US health systems. It also claims a 5–7 percent yield boost and a 50 percent reduction in cost to collect for clients, though those figures lack external audit references.